Cancer Treatments
Newfound Mechanism May Explain Why Some Cancer Treatments Boost Risk of Heart Disease
NYU Langone Health
PR-12-24-NI-122Dec 02, 2024
Drug Approval
U.S. FDA Approves VYNDAQEL® and VYNDAMAX™ for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease
Pfizer
PR-M05-19-NI-036May 13, 2019
Drug Development
Novartis Licenses First-in-Class Heart Disease Drug
Emilie Branch
Pharma's Almanac
PAO-M03-19-NI-008Mar 05, 2019